Pharmacodynamics of MDL 72974A: absence of effect on the pressor response to oral tyramine

  • C. Hinze
  • M. Kaschube
  • J. Hardenberg
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)


MDL 72974A, a new irreversible selective inhibitor of monoa-mine oxidase (MAO)-B which is not metabolized to amphetamine-like compounds, is currently being developed for the treatment of Parkinson’s disease. In this double blind, placebo controlled randomized study 24 healthy volunteers (n = 6/dose) received single oral doses of placebo, 1, 12 or 24 mg of MDL 72974A qd over two weeks. Sensitivity to orally administered tyramine was determined under fasting conditions before and after drug administration and the doses of tyramine yielding a 30 mmHg increase of SBP (PD30) compared. The 2-fold increase of tyramine sensitivity at end of treatment seen at all MDL 72974A dose levels, however, is within the variability range of the tyramine pressor response. MDL 72974A selectively inhibits MAO-B at doses up to 24 mg orally and has a favourable safety profile.


mmHg Increase Oral Tyramine Tyramine Pressor Tyramine Sensitivity Irreversible Selective Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ (1989) Determination and comparison of the pressor effect of tyramine during long-term moclo-bemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther 46: 344–351.PubMedCrossRefGoogle Scholar
  2. Bieck PR, Firkusny L, Schick C, Antonin K-H, Nilsson E, Schulz R, Schwenk M, Wollmann H (1989) Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 45: 260–269.PubMedCrossRefGoogle Scholar
  3. Burn JH, Rand MJ (1958) The action of sympathomimetic amines in animals treated with reserpine. J Physiol 144: 314–346.PubMedGoogle Scholar
  4. Davey MJ, Farmer JB (1963) The mode of action of tyramine. J Pharm Pharmacol 15: 178–182.PubMedCrossRefGoogle Scholar
  5. Elsworth JD, Glover V, Reynolds GP (1978) Deprenyl administration in man: a selective monoamine oxidase-B inhibitor without the “cheese effect”. Psychopharmacology 57: 33–38.PubMedCrossRefGoogle Scholar
  6. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–97.PubMedCrossRefGoogle Scholar
  7. Reimann IW, Firkusny L, Antonin KH, Bieck PR (1992) Intravenous amine pressor tests in healthy volunteers. Eur J Clin Pharmacol 42: 137–141.PubMedCrossRefGoogle Scholar
  8. Schulz R, Antonin K-H, Hoffmann E, Jedrychowski M, Nilsson E, Schick C, Bieck PR (1989) Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. Clin Pharmacol Ther 46: 528–536.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • C. Hinze
    • 1
  • M. Kaschube
    • 1
  • J. Hardenberg
    • 2
  1. 1.Marion Merrell DowClinical Pharmacology UnitKehlFederal Republic of Germany
  2. 2.Department of Clinical ResearchStrasbourgFrance

Personalised recommendations